[ET Net News Agency, 16 September 2021] SciClone Pharmaceuticals (Holdings) Limited
(06600) said the company has entered into a collaboration and licence agreement with
Tarveda Therapeutics, Inc. (Tarveda), pursuant to which Tarveda grants an exclusive
licence to permit the company to develop, manufacture and commercialise a
preclinical-stage product portfolio of miniature drug conjugates that consists of a
phosphoinositide 3-kinase (PI3K) inhibitor (undisclosed) payload moiety, a linker and a
heat shock protein 90 (HSP90) binding moiety in Greater China, including mainland China,
Hong Kong, Macau and Taiwan.
The company will pay Tarveda an upfront fee in cash with the right to make an equity
investment in Tarveda and make additional payments upon achievement of various
pre-determined development, regulatory approval and commercial sales milestones. Further,
Tarveda will be eligible to receive royalties based on net sales of the licensed product
portfolio in Greater China.
This agreement builds on the company and Tarveda's existing exclusive licensing
agreement signed in March 2020 to partner in Greater China for PEN-866. The company is
pleased to expand further its collaboration and strategic partnership with Tarveda and
believes the closer relationship will complement the advantages of both the company and
Tarveda in pre-clinical research, clinical development and other aspects. (RC)